Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pamrevlumab in neoadjuvant therapy for unresectable locally advanced pancreatic cancer
CTR20202359Phase 3Completed
- Sponsor
- FibroGen
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pamrevlumab in pancreatic adenocarcinoma (PDAC), sponsored by FibroGen. Started Nov 2020; status: completed.
02
Drugs
pamrevlumab
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on CTR20202359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202359.